There's been a notable change in appetite for KORU Medical Systems, Inc. (NASDAQ:KRMD) shares in the week since its quarterly report, with the stock down 14% to US$3.55. It was overall a positive result, with revenues beating expectations by 4.0% to hit US$12m. KORU Medical Systems also reported a statutory profit of US$0.01, which was a nice improvement from the loss that the analysts were predicting. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.

Taking into account the latest results, the most recent consensus for KORU Medical Systems from five analysts is for revenues of US$48.1m in 2026. If met, it would imply an okay 6.6% increase on its revenue over the past 12 months. Per-share losses are supposed to see a sharp uptick, reaching US$0.047. Before this latest report, the consensus had been expecting revenues of US$48.7m and US$0.044 per share in losses. Overall it looks as though the analysts were a bit mixed on the latest consensus updates. Although revenue forecasts held steady, the consensus also made a modest increase to its losses per share forecasts.

As a result, there was no major change to the consensus price target of US$6.60, with the analysts implicitly confirming that the business looks to be performing in line with expectations, despite higher forecast losses. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. The most optimistic KORU Medical Systems analyst has a price target of US$8.00 per share, while the most pessimistic values it at US$5.00. There are definitely some different views on the stock, but the range of estimates is not wide enough as to imply that the situation is unforecastable, in our view.

Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. We can infer from the latest estimates that forecasts expect a continuation of KORU Medical Systems'historical trends, as the 14% annualised revenue growth to the end of 2026 is roughly in line with the 14% annual growth over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to see their revenues grow 7.6% per year. So it's pretty clear that KORU Medical Systems is forecast to grow substantially faster than its industry.

The Bottom Line

The most important thing to take away is that the analysts increased their loss per share estimates for next year. Happily, there were no major changes to revenue forecasts, with the business still expected to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. At Simply Wall St, we have a full range of analyst estimates for KORU Medical Systems going out to 2028, and you can see them free on our platform here..

We also provide an overview of the KORU Medical Systems Board and CEO remuneration and length of tenure at the company, and whether insiders have been buying the stock, here.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.